Get started

Biotech

Symmetrical Triangle BreakoutEYPT chart is building up for another run. Potential catalyst before year end with an sNDA for Short Duration Yutiq. accumulation has been slow and steady indicating EYPT oversold conditions. Technical's: weekly chart --> Harmonic Gartley (bounced off significant support level) and been in uptrend since. Symmetrical Triangle/ Breakout setup has been known to act as a pre-courser to huge upside moves (40%+). Bull flag building in the symmetrical triangle. . . Read the rest then check out the rest of our trade ideas HERE Disclosure: I am long EYPT. I am not a financial advisor and this is not a buy/ sell recommendation but for education purposes only. Please do your homework before investing.
NASDAQ:EYPTLong
by follow_the_money
#VolatilityWatch Solid BioscencesBiotech buyouts have been very strong, especially with Gene therapy stocks as of late. Bounced off Lower end of channel Gartley pattern bounced off 1.618 fib extension along with important reversal leg of Elliott Wave Theory. if price holds inside the lower end of the channel there is a potential move back up and test the gap. looking for nice $0.40+ swing from current level. Disclosure: I am long SLDB. I may buy/ sell within the next 72 hours. I am not a financial adviser. Please do your homework before investing.
NASDAQ:SLDBLong
by follow_the_money
Buy the dip in SAVA based on strong Alzheimer's trial dataCassava Sciences (SAVA) just got some positive clinical trial data on their Alzheimer’s drug. The result caused one analyst firm to upgrade SAVA’s price target from $3.00 per share to $6.00 per share. SAVA’s got a 9.4/10 analyst summary score, with most analysts rating the stock a “buy.” I entered SAVA Friday morning at $2.16 per share. It’s already up almost 100% from its share price last month, but I think it could continue its run next week.
NASDAQ:SAVALong
by ChristopherCarrollSmith
1
Targovax $TRVX.OL clinical phase oncolytic virus valued 35 mUSDTargovax OSL:TRVX a clinical phase norwegian Biotech is currently at market cap NOK 327 million / 35 million USD. Value inflection point very close as the company will need to raise funds in the very near future, which must either come from investors or from a possible partner deal. PRESENTATION OF ONCOS-102 MELANOMA DATA AT SITC ANNUAL MEETING www.healthcap.eu Q3 report: www.targovax.com Q3 transcript: finance.yahoo.com
C
by savepiginvest
Photocure $PHO.OL stock trade above resistance, close at 5yr hghRecent news by OSL:PHO : Randomized phase 3 study in Denmark demonstrates significant advantage in Bladder Cancer for Hexvix/Cysview blue light cystoscopy over standard white light variant: photocure.com At Q3 2019 Photocure reported continued record growth in the US as well as upfront payments from Chinese partner Asieris: photocure.com Further improvements for US reimbursements for Cysview from january 2020: photocure.com Technical analysis: Technical indicators sliding into high momentum and near overbought values at this price level, so any entry should be done with clear considerations of short term risks.
OSL:PHO
by savepiginvest
Some upside potential in Athenex after sales beatAnalysts have been lowering their earnings forecasts on Athenex, Inc., causing the stock to crash. However, the company not only met earnings expectations on its report this morning, but also beat sales expectations and raised its full-year revenue guidance from a 32.5% increase to a 37.5% increase year-over-year. That's a pretty big bump, and it could cause analysts to revise their views on the company in the coming weeks. One or two upgrades could send this stock climbing back to the $14-15 range. A long-term risk is the company's financial health. Athenex operates at a large loss and only has cash to fund operations until late 2020. The company is expected to make some progress toward profitability by then, but it will still be a long way from achieving that goal. So this is not a safe long-term investment; it's just a short-term scalp.
ALong
by ChristopherCarrollSmith